Invesco Biotechnology & Genome ETF
PBE
89 hedge funds and large institutions have $63M invested in Invesco Biotechnology & Genome ETF in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 27 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
10% more capital invested
Capital invested by funds: $57.3M → $63M (+$5.73M)
3.69% more ownership
Funds ownership: 24.87% → 28.57% (+3.7%)
0% more funds holding
Funds holding: 89 → 89 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
67% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GKWIM
Gerber Kawasaki Wealth & Investment Management
Santa Monica,
California
|
+$8.95M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.69M |
| 3 |
M&T Bank
Buffalo,
New York
|
+$1.16M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$378K |
| 5 |
SB
Strategic Blueprint
Atlanta,
Georgia
|
+$290K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$707K |
| 2 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$358K |
| 3 |
Morgan Stanley
New York
|
-$340K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$297K |
| 5 |
BCM
Beck Capital Management
Austin,
Texas
|
-$292K |
PBE Hedge Fund Activity: Q2 2022 in Review
89 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2022, worth a combined $63M — up 10% from $57.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PBE positions and 6 closed out — a net gain of 1 holder — while 9 added to existing stakes and 27 trimmed.
The largest buyer was Gerber Kawasaki Wealth & Investment Management, adding an estimated $8.95M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $707K sold.
- 89 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $63M of Invesco Biotechnology & Genome ETF stock for Q2 2022, up 10% quarter-over-quarter.
- 7 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2022 and 6 closed out, a net change of +1 holder.
- The largest Invesco Biotechnology & Genome ETF buyer in Q2 2022 was Gerber Kawasaki Wealth & Investment Management, an estimated $8.95M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q2 2022 was Susquehanna International Group, an estimated $707K sold.
Based on aggregated 13F filings for Q2 2022.